Image

Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy

Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy

Recruiting
18-99 years
All
Phase N/A

Powered by AI

Overview

This research is studying how a food product (resistant potato starch) which is a dietary supplement made from potato starch affects the gut bacteria of people with cirrhosis and hepatic encephalopathy.

The researchers in this study want to understand how potato starch works in the subject's body and how the body will react to it. Along with taking the study product participants health-related information and stool will be collected for this research study.

Eligibility

Inclusion Criteria:

  • Able to provide consent, with signed and dated informed consent form.
  • Stated willingness to comply with all study procedures and availability for the duration of the study.
  • Diagnosis of cirrhosis based on liver biopsy, imaging, or evidence of clinical decompensation.
  • History of at least one episode of overt Hepatic Encephalopathy (HE) in the last year.
    • Defined by West Haven Criteria Grades II to IV
    • Can be precipitated Hepatic Encephalopathy (HE) episode.
  • Sexually active women of childbearing potential enrolled in the study must agree to use a highly-effective method of contraception (defined in the protocol) for the duration of the study.

Exclusion Criteria:

  • Hospitalization in the last 4 weeks
  • Current refractory ascites (requiring large volume paracentesis to manage ascites)
  • Gut-absorbable or intravenous antibiotic therapy in the last 4 weeks (rifaximin is permitted)
  • Anticipated antibiotics in the coming 4 weeks
  • Use of lactulose in the last 4 weeks
  • Alcohol or illicit drug intake in the last 4 weeks
    • By history
    • Alcohol use will be characterized as \>1 alcoholic drink / week
  • History of inflammatory bowel disease
  • History of primary sclerosing cholangitis
  • Total bilirubin in the last 3 months \> 4 mg/dL
  • Prior diagnosis of dementia or other primary neurocognitive disorder
  • Pregnancy or breast feeding
  • Placement of a portosystemic shunt or transjugular intrahepatic portosystemic shunt in the last 3 months (permissible if placed \>3 months before enrollment)
  • Allergy to resistant potato starch

Study details
    Hepatic Encephalopathy
    Cirrhosis

NCT06425380

Mayo Clinic

1 February 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.